CTLA4 and Alzheimer disease: In one other report from Arruda et al. in 2023, a 20-year-old female patient with severe steroid-resistant AD and a different pathologic variant of CTLA-4 experienced significant improvement when treated with Dupilumab.9 Over 12 months, the patient’s EASI score decreased from 80.7 to 25.5 while her DLQI reduced from 27 to 1.